Treating Chronic Neuropathic Resulting from Cancer Chemotherapy and Other Disorders

SLU ID 13-020 | Treating Chronic Neuropathic Using Phenotype Screening

Intellectual Property Status

Seeking

  • Know-how based
  • Licensee
  • Development partner

Background

Chronic neuropathic pain (CNP) is a widespread condition often associated with diabetes, cancer, injury, exposure to toxic substances, and a variety of other conditions. When it occurs in association with cancer chemotherapy, patients often must discontinue life-saving treatment. Current therapies for CNP have low efficacy and produce a range of side effects including liver toxicity, addiction, and personality changes. As such there is a significant need for novel CNP treatments. Researchers at Saint Louis University have developed approaches to treating CNP that potentially overcome many of the limitations of currently available therapies.

Overview

Saint Louis University researchers have developed a method of treating or preventing chronic neuropathic pain (CNP) that involves administering an A3AR agonist. The A3AR agonist may be IB-MECA, Cl-IB-MECA, or an adenosine methanocarba derivative including, but not limited to, MRS 5698, MRS5980, or MRS7154. The method is applicable to both humans and non-human mammals.

Benefits

The potential benefits of this technology include:

  • Increase effectiveness of therapies
  • Minimize potential for drug addiction
  • Minimize the need to terminate life-saving chemotherapy treatments
  • Minimize risk of liver toxicity

Applications

This technology has potential application for treating chronic neuropathic (CNP) pain associated with a variety of

disorders including:

  • Diabetes
  • Cancer chemotherapy

Opportunity

Saint Louis University is seeking partners to further develop and commercialize this technology.